Major Depressive Disorder - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Major Depressive Disorder Pipeline Review, H2 2016, provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape.

Major depressive disorder (MDD) is a mental disorder characterized by a pervasive and persistent low mood that is accompanied by low self-esteem and by a loss of interest or pleasure in normally enjoyable activities. Symptoms of MDD include agitation, restlessness, and irritability, anger, becoming withdrawn or isolated, fatigue and lack of energy, feeling hopeless and helpless, worthless, guilty, self-hate, loss of interest or pleasure in activities that were once enjoyed, sudden change in appetite, often with weight gain or loss, thoughts of death or suicide, trouble concentrating and trouble sleeping or sleeping too much.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Major Depressive Disorder Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Major Depressive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Major Depressive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 18, 11, 1, 8 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Major Depressive Disorder.

Major Depressive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Major Depressive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Major Depressive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Major Depressive Disorder (Central Nervous System) therapeutics a